BREKIYA (AUTOINJECTOR)

Launch

dihydroergotamine mesylate

NDASUBCUTANEOUSSOLUTION
Approved
May 2025
Lifecycle
Launch
Competitive Pressure
0/100

Mechanism of Action

5-HT 1Dα and 5-HT 1Dβ receptors. The therapeutic activity of dihydroergotamine in migraine is generally attributed to the agonist effects at 5-HT 1D receptors.

Indications (3)

hemiplegic migrainemigraine with brainstem auramigraine

Loss of Exclusivity

LOE Date
Feb 26, 2039
158 months away
Patent Expiry
Feb 26, 2039

Patent Records (4)

Patent #ExpiryTypeUse Code
10532049
Feb 26, 2039
Product
—
11304942
Feb 26, 2039
Product
—
11819501
Feb 26, 2039
U-4188
12533351
Feb 26, 2039
Product
—
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers